Engineered extracellular vesicles derived from primary M2 macrophages with anti-inflammatory and neuroprotective properties for the treatment of spinal cord injury


Posted: 2021-11-18 20:00:00
Background: Uncontrollable inflammation and nerve cell apoptosis are the most destructive pathological response after spinal cord injury (SCI). So, inflammation suppression combined with neuroprotection is one of the most promising strategies to treat SCI. Engineered extracellular vesicles with anti-inflammatory and neuroprotective properties are promising candidates for implementing these strategies for the treatment of SCI. Results: By combining nerve growth factor (NGF) and curcumin (Cur), we prepared stable engineered extracellular vesicles of approximately 120 nm from primary M2 macrophages with anti-inflammatory and neuroprotective properties (Cur@EVs-cl-NGF). Notably, NGF was coupled with EVs by matrix metalloproteinase 9 (MMP9)-a cleavable linker to release at the injured site accurately. Through targeted experiments, we found that these extracellular vesicles could actively and effectively accumulate at the injured site of SCI mice, which greatly improved the bioavailability of the drugs. Subsequently, Cur@EVs-cl-NGF reached the injured site and could effectively inhibit the uncontrollable inflammatory response to protect the spinal cord from secondary damage; in addition, Cur@EVs-cl-NGF could release NGF into the microenvironment in time to exert a neuroprotective effect against nerve cell damage. Conclusions: A series of in vivo and in vitro experiments showed that the engineered extracellular vesicles significantly improved the microenvironment after injury and promoted the recovery of motor function after SCI. We provide a new method for inflammation suppression combined with neuroprotective strategies to treat SCI. Keywords: Curcumin; Extracellular vesicles; M2 repolarization; Neuroprotection; Spinal cord injury.

参考サイト PubMed: exsome


Powered by Stromvergleich


バイオクイックニュース日本語版:エクソソーム特集

バイオクイックニュース日本語版
5月 24, 2019 バイオアソシエイツ

免疫療法抵抗性腫瘍はリンパ節に移動して免疫細胞活性化を遠隔的に阻害するPD-L1が詰まったエクソソームを輸送することが発見された

チェックポイント阻害剤として知られている免疫療法薬は癌の治療に革命をもたらした。最近まで治療不可能と考えられていた悪性腫瘍を持つ多くの患者が長期寛解を経験している。…

ゲスト 541人 と メンバー 6人 がオンラインです